Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Sep 16, 2010

Premium

WaferGen Biosystems this week said that it has appointed Donald Huffman as its new chief financial officer.

Huffman was most recently CFO at Asante Solutions, a medical device company developing a drug-delivery pump. Prior to that, he was CFO at Guava Technologies, EndoSonics, Microcide Pharmaceuticals, Celtrix Pharmaceuticals, and Sanderling Ventures, a biomedical venture capital firm.


Hugh Douglas has joined BioCision as chief operating officer.

Douglas most recently led Bridge4Bio, a global business consulting group. Previously, he was managing director and president of Hoefer, a part of Harvard Bioscience. Douglas was also vice president of the West Coast operations for Amersham Biosciences, now a part of GE Healthcare.

The company has also expanded its corporate advisory board. New members include Lori Kunkel, who has served as chief medical officer at Proteolix/Onyx Pharmaceuticals, vice president of clinical development at Xenocor, and has held other senior positions at Genentech, Chiron, and Genitope; and Paul Nowak, currently CEO of Biotix Holdings and previously CEO and president of VWR International.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.